{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T21:10:42Z","timestamp":1777929042159,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2009,6,23]],"date-time":"2009-06-23T00:00:00Z","timestamp":1245715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"abstract":"<jats:p>Twenty-one patients with previously untreated acute leukemia were treated with a combination chemotherapy of 120\u2013200 mg\/m2 of aclacinomycin A (ACM-A) in five divided daily doses and behenoyl-arabinofuranosylcytosine (BH-AC) 200\u2013250 mg\/m2 for 7 days at Saitama Cancer Center between April 1980 and July 1983. Complete remission was obtained in 12 of 21 patients (57.1%; M1 0\/1, M2 10\/10, M3 0\/2, M4 1\/3, leukemic transformation from sideroblastic anemia 0\/1, refractory anemia with excess of blasts in transformation 1\/2, chronic myelomonocytic leukemia 0\/1). Seven of 9 patients who failed to have complete remission were crossed over to a combination chemotherapy of daunorubicin (DNR) plus BH-AC or cytosine arabinoside (ara-C), or single DNR for patients with M3, yielding complete remission in 5 patients. Seven patients received a total cumulative dose of more than 600 mg\/m2 of ACM-A. The maximum dose given was 2,000 mg\/m2. No congestive heart failure has yet been experienced. The median survival time was 12 months. These results have demonstrated that a combination of ACM-A and BH-AC shows almost equivalent activity with that of a standard induction therapy consisting of DNR plus ara-C. In addition, it was suggested that ACM-A plus BH-AC could be incorporated into reinforcement therapy because of supposedly less cardiac toxicity.<\/jats:p>","DOI":"10.1159\/000226097","type":"journal-article","created":{"date-parts":[[2009,6,24]],"date-time":"2009-06-24T11:52:41Z","timestamp":1245844361000},"page":"18-22","source":"Crossref","is-referenced-by-count":1,"title":["Aclacinomycin A and Behenoyl Arabinofuranosylcytosine Combination Chemotherapy for Previously Untreated Acute Leukemia"],"prefix":"10.1159","author":[{"given":"Kazumi","family":"Sampi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiko","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masao","family":"Hattori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2009,6,23]]},"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/226097","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000226097","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T23:26:41Z","timestamp":1777678001000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000226097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6,23]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000226097","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"value":"0030-2414","type":"print"},{"value":"1423-0232","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,6,23]]}}}